Decision making for systemic treatment of non-small-cell lung cancer

Susan Mayor

Non-small-cell lung cancers (NSCLC) covers a heterogeneous group of diseases, accounting for around 80% of all lung cancers, which were previously lumped together because there was no apparent reason to use different therapeutic approaches for the various histologies. This has now changed, and choosing the best treatment option for NSCLC patients is increasingly complex.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1